OraSure Technologies, Inc. announced it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
The initial contract award is valued at approximately $7.5 million over multiple years during the base period, with a potential value of up to $11 million. This funding is specifically allocated for the development to achieve U.S. Food and Drug Administration (FDA) 510(k) clearance for a single-use lateral flow immunoassay.
The proposed test is intended for the qualitative detection of antigens from Marburg viruses, for use with specimens from individuals with epidemiological risk factors who show signs or symptoms of MVD, or from recently deceased individuals suspected of MVD. This initiative highlights OraSure's commitment to addressing global public health challenges and leveraging its expertise in rapid diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.